Stryker's projection of higher-than-expected organic net sales growth and adjusted EPS for 2024 is a positive signal for investors, likely leading to an optimistic outlook on the stock in the short term. The company's effective pricing strategy, resulting in a flat impact on the full year, suggests efficient management and could further bolster investor confidence.